Physicians' Academy for Cardiovascular Education

PCSK9 inhibitor lowers CV risk in peripheral artery disease and in high-risk patients with previous MI

Evolocumab and Outcomes in Patients with Peripheral Artery Disease (Bonaca) & Clinical Benefit of Evolocumab in Patients with a History of MI: An Analysis from FOURIER (Sabatine)

Presented at AHA 2017 Scientific Sessions in Anaheim, CA, USA by Marc Bonaca and Marc Sabatine (Brigham and Women’s Hospital, Boston, MA, USA)

News - Nov. 21, 2017

Main results

Findings in patients with PAD

Findings in patients with MI

Conclusion

It results from the PAD analysis that these patients, with a higher risk of both MACE and MALE, benefit from treatment with evolocumab in the reduction of these events. Benefits extend to PAD patients without prior MI or stroke. Thus, dr Bonaca concluded that LDL-C reduction to very low levels should be considered in patients with PAD, regardless of history of MI or stroke, to reduce the risk of MACE and MALE.

The other analysis showed that patients closer to their most recent MI, with multiple prior MIs, or with multivessel disease, are at 34-90% risk for major vascular events. These patients experience both substantial relative and absolute risk reductions with intensive LDL-C lowering with evolocumab. These readily ascertainable clinical features offer one approach to tailoring therapy.

Disclosures

Share this page with your colleagues and friends: